Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

被引:2
作者
Heintjes, E. M. [1 ]
Houben, E. [1 ]
Beekman-Hendriks, W. L. [2 ]
Lighaam, E. [2 ]
Cremers, S. M. [2 ]
Penning-van Beest, F. J. A. [1 ]
Stehouwer, C. D. A. [3 ,4 ]
Herings, R. M. C. [5 ]
机构
[1] PHARMO Inst Drug Outcomes Res, Utrecht, Netherlands
[2] AstraZeneca BV, The Hague, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands
[4] Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands
关键词
Cardiovascular events; glucose-lowering drugs; mortality; risk factor control; type; 2; diabetes; MICROVASCULAR OUTCOMES; METAANALYSIS; DISEASE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Quality of diabetes care in the Netherlands ranked second in the Euro Diabetes Index 2014, but data on outcomes are lacking. We assessed trends in cardiovascular disease and mortality among type 2 diabetes (T2DM) patients in the context of risk factor control. Methods: Annual cohorts of adult T2DM patients were constructed from the PHARMO Database Network. Age-standardised mortality rates and incidence rates (IR) of hospitalisations for acute myocardial infarction (AMI), stroke, and congestive heart failure (CHF) were compared with a diabetes-free population matched on age, sex, and general practitioner. Life years lost (LYL) to T2DM or cardiovascular disease were determined by comparing life expectancy between matched groups. Proportions attaining glycated haemoglobin (HbAic), blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C) goals were assessed annually. Results: Among 53,602 T2DM patients, slight increases in IR between 2008 and 2016 were proportional to those in diabetes-free controls; on average T2DM increased the risk of mortality by 86%, hospitalisation for AMI 69%, stroke 57%, and CHF 185%. At age 55, LYL to T2DM averaged 3.5 years and established CVD added 1.8 years, irrespective of sex. HbAIc goal attainment increased from 58% to 65%, LDL-C from 56% to 65%, and systolic BP from 57% to 72%. Conclusion: Despite highly organised diabetes care, excess incident cardiovascular events and mortality due to T2DM did not decrease over the study period. Life expectancy of T2DM patients is significantly reduced and risk factor control is suboptimal. This suggests there is considerable room for improvement of diabetes care in the Netherlands.
引用
收藏
页码:317 / 329
页数:13
相关论文
共 33 条
[1]   Introduction [J].
不详 .
DIABETES CARE, 2017, 40 :S1-S130
[2]  
[Anonymous], 2013, Huisarts Wetenschap
[3]   Blood pressure targets for hypertension in patients with type 2 diabetes [J].
Aronow, Wilbert S. ;
Shamliyan, Tatyana A. .
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (11)
[4]  
Bjornberg A, 2017, EURO DIABETES INDEX
[5]  
CBS, 2017, BEV GESL LEEFT BURG
[6]   Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE [J].
Cornell, Susan .
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2017, 57 (02) :261-265
[7]   Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events [J].
Douros, Antonios ;
Yin, Hui ;
Yu, Oriana Hoi Yun ;
Filion, Kristian B. ;
Azoulay, Laurent ;
Suissa, Samy .
DIABETES CARE, 2017, 40 (11) :1506-1513
[8]   Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality [J].
Eriksson, Jan W. ;
Bodegard, Johan ;
Nathanson, David ;
Thuresson, Marcus ;
Nystrom, Thomas ;
Norhammare, Anna .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 117 :39-47
[9]  
Gerstein HC, 2011, NEW ENGL J MED, V364, P818, DOI 10.1056/NEJMoa1006524
[10]   Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study [J].
Grover, Steven A. ;
Kaouache, Mohammed ;
Rempel, Philip ;
Joseph, Lawrence ;
Dawes, Martin ;
Lau, David C. W. ;
Lowensteyn, Ilka .
LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (02) :114-122